Insider · CIK 0002027157
Leon Hooftman
Files at BRNS (Barinthus Biotherapeutics plc.). First filing -, latest -.
Leon Hooftman files SEC Form 4 as officer at BRNS (Barinthus Biotherapeutics plc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Leon Hooftman has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 5 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 9, 2026 | BRNS Barinthus Biotherapeutics plc. | AGrant or award Ordinary Shares | +361,530 | - | - | 361,530 | 34 d ago |
| Sep 9, 2026 | BRNS Barinthus Biotherapeutics plc. | DDisposition to issuer Ordinary Shares | -361,530 | - | - | 0 | 34 d ago |
| Sep 9, 2026 | BRNS Barinthus Biotherapeutics plc. | DDisposition to issuer Share Option (Right to Buy)derivative | -195,166 | $0.00 | $0 | 0 | 34 d ago |
| Sep 9, 2026 | BRNS Barinthus Biotherapeutics plc. | DDisposition to issuer Share Option (Right to Buy)derivative | -140,000 | $0.00 | $0 | 0 | 34 d ago |
| Feb 3, 2025 | BRNS Barinthus Biotherapeutics plc. | AGrant or award Share Option (Right to Buy)derivative | +140,000 | $0.00 | $0 | 140,000 | Feb 5, 2025 |
Questions about Leon Hooftman
Answered from the filings on this page, as of the latest one.
Is Leon Hooftman buying or selling?
Leon Hooftman has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Leon Hooftman's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Leon Hooftman has 0.
Where does Leon Hooftman file Form 4?
Leon Hooftman has filed Form 4 at BRNS (Barinthus Biotherapeutics plc.) as Chief Medical Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.